JP7254029B2 - Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 - Google Patents

Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 Download PDF

Info

Publication number
JP7254029B2
JP7254029B2 JP2019558645A JP2019558645A JP7254029B2 JP 7254029 B2 JP7254029 B2 JP 7254029B2 JP 2019558645 A JP2019558645 A JP 2019558645A JP 2019558645 A JP2019558645 A JP 2019558645A JP 7254029 B2 JP7254029 B2 JP 7254029B2
Authority
JP
Japan
Prior art keywords
cdr
binding agent
syndecan
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019558645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517725A5 (https=
JP2020517725A (ja
Inventor
ジュリア・コロネラ
ロビン・リチャードソン
アンジュリ・ティマー
ローランド・ニューマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JP2020517725A publication Critical patent/JP2020517725A/ja
Publication of JP2020517725A5 publication Critical patent/JP2020517725A5/ja
Priority to JP2023001655A priority Critical patent/JP2023058488A/ja
Application granted granted Critical
Publication of JP7254029B2 publication Critical patent/JP7254029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019558645A 2017-04-26 2018-04-25 Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 Active JP7254029B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023001655A JP2023058488A (ja) 2017-04-26 2023-01-10 Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490463P 2017-04-26 2017-04-26
US62/490,463 2017-04-26
PCT/JP2018/016847 WO2018199176A1 (en) 2017-04-26 2018-04-25 Syndecan-1 (cd138) binding agents and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023001655A Division JP2023058488A (ja) 2017-04-26 2023-01-10 Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用

Publications (3)

Publication Number Publication Date
JP2020517725A JP2020517725A (ja) 2020-06-18
JP2020517725A5 JP2020517725A5 (https=) 2021-05-27
JP7254029B2 true JP7254029B2 (ja) 2023-04-07

Family

ID=63918582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558645A Active JP7254029B2 (ja) 2017-04-26 2018-04-25 Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用
JP2023001655A Withdrawn JP2023058488A (ja) 2017-04-26 2023-01-10 Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023001655A Withdrawn JP2023058488A (ja) 2017-04-26 2023-01-10 Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用

Country Status (5)

Country Link
US (1) US11242403B2 (https=)
EP (1) EP3615573A4 (https=)
JP (2) JP7254029B2 (https=)
CN (1) CN110691793A (https=)
WO (1) WO2018199176A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1（cd138）结合剂及其用
AU2019353367A1 (en) * 2018-10-02 2021-02-18 Mitsubishi Tanabe Pharma Corporation Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
US20230272041A1 (en) 2020-04-22 2023-08-31 Dragonfly Therapeutics, Inc. Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
WO2023220542A1 (en) * 2022-05-10 2023-11-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Utilization of immortalized b cells to identify sdcbp as a novel therapeutic target in ovarian carcinoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080829A1 (en) 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2240516B1 (en) * 2007-12-26 2015-07-08 Biotest AG Methods and agents for improving targeting of cd138 expressing tumor cells
NZ613647A (en) * 2009-05-06 2015-02-27 Biotest Ag Uses of immunoconjugates targeting cd138
WO2014059442A2 (en) * 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1（cd138）结合剂及其用
MX2020003783A (es) * 2017-10-02 2021-01-08 Visterra Inc Moleculas de anticuerpo de cd138 y sus usos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080829A1 (en) 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood, 2004, Vol.104, No.12, pp.3688-3696

Also Published As

Publication number Publication date
WO2018199176A1 (en) 2018-11-01
CN110691793A (zh) 2020-01-14
JP2023058488A (ja) 2023-04-25
US11242403B2 (en) 2022-02-08
EP3615573A4 (en) 2021-01-20
US20200181278A1 (en) 2020-06-11
JP2020517725A (ja) 2020-06-18
EP3615573A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
JP7254029B2 (ja) Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用
JP6297088B2 (ja) Ｐｃｓｋ９アンタゴニスト
TWI770065B (zh) Ｃｍｅｔ單株結合劑、其藥物複合體及其用途
CN102574923A (zh) 针对人蛋白酶激活受体-2的高亲和力人抗体
US10202450B2 (en) Nav 1.7 antibodies and methods of using the same
TW202302650A (zh) 針對dll3的結合分子及其應用
ES2778100T3 (es) Anticuerpos monoclonales anti-gpc-1 y usos de los mismos
WO2021107823A2 (ru) Высокоспецифические антитела к белку prame и их применение
KR20250096769A (ko) 글리피칸-3에 대한 이중특이성 항체 및 이의 용도
JP2021165268A (ja) シンデカン−１および線維芽細胞増殖因子受容体を標的とする二重特異性結合物質を含む医薬組成物
JP2022514148A (ja) シンデカン－１および線維芽細胞増殖因子受容体を標的とする二重特異性結合物質
US20240262899A1 (en) Anti-cith3 antibodies and uses thereof
TW201139667A (en) Amyloid-beta binding proteins
JP2025082818A (ja) 遺伝子組換え抗体、それを含むキット、およびがん診断におけるその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230110

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230117

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230328

R150 Certificate of patent or registration of utility model

Ref document number: 7254029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150